therapeutic strategy

MDA 2024: Blocking protein shows promise for genetic form of ALS

Blocking a protein called PTP sigma led to better nerve survival and motor function in a mouse model of amyotrophic lateral sclerosis (ALS) caused by mutations in the C9ORF72 gene — leading the researchers to highlight this strategy for potentially treating this genetic ALS form. Data from cell models…

Disarm Therapeutics Receives Key Funding for ALS Therapy Development

Research into the development of new therapies to treat several traumatic, inflammatory, and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) received an important financial boost with the announcement by Disarm Therapeutics that it will receive $30 million in financing to develop treatments for axonal degeneration. Disarm was founded in 2016 as a…

Perturbed Transport into Cellular Nucleus Linked to ALS

Three recent studies published in the journals Nature and Nature Neuroscience identified a mutation in some forms of amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) that leads to neuronal death by disrupting the movement of molecules within the cellular nucleus. ALS and FTD are characterized by death…